These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 14727218)

  • 1. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
    Zaccarelli M; Perno CF; Forbici F; Soldani F; Bonfigli S; Gori C; Trotta MP; Bellocchi MC; Liuzzi G; D'Arrigo R; De Longis P; Boumis E; Bellagamba R; Tozzi V; Narciso P; Antinori A
    Clin Infect Dis; 2004 Feb; 38(3):433-7. PubMed ID: 14727218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.
    Quiros-Roldan E; Bertelli D; Signorini S; Airoldi M; Torti C; Moretti F; Carosi G
    Microbios; 2001; 106(414):137-45. PubMed ID: 11506064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
    Trotta MP; Bonfigli S; Ceccherini-Silberstein F; Bellagamba R; D'Arrigo R; Soldani F; Zaccarelli M; Concetta Bellocchi M; Lorenzini P; Marconi P; Boumis E; Forbici F; Comandini UV; Tozzi V; Narciso P; Federico Perno C; Antinori A
    J Med Virol; 2006 May; 78(5):535-41. PubMed ID: 16555278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
    Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
    Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
    Campbell TB; Shulman NS; Johnson SC; Zolopa AR; Young RK; Bushman L; Fletcher CV; Lanier ER; Merigan TC; Kuritzkes DR
    Clin Infect Dis; 2005 Jul; 41(2):236-42. PubMed ID: 15983922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
    Van Laethem K; Pannecouque C; Vandamme AM
    Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
    Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA
    Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
    J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
    Antinori A; Trotta MP; Lorenzini P; Torti C; Gianotti N; Maggiolo F; Ceccherini-Silberstein F; Nasto P; Castagna A; De Luca A; Mussini C; Andreoni M; Perno CF;
    Antivir Ther; 2007; 12(8):1175-83. PubMed ID: 18240858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.
    Weinstock HS; Zaidi I; Heneine W; Bennett D; Garcia-Lerma JG; Douglas JM; LaLota M; Dickinson G; Schwarcz S; Torian L; Wendell D; Paul S; Goza GA; Ruiz J; Boyett B; Kaplan JE
    J Infect Dis; 2004 Jun; 189(12):2174-80. PubMed ID: 15181563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
    Novak RM; Chen L; MacArthur RD; Baxter JD; Huppler Hullsiek K; Peng G; Xiang Y; Henely C; Schmetter B; Uy J; van den Berg-Wolf M; Kozal M;
    Clin Infect Dis; 2005 Feb; 40(3):468-74. PubMed ID: 15668873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.